Komzifti in Bangladesh

Komzifti - overview

Komzifti (ziftomenib) is an oral menin inhibitor developed by Kura Oncology and approved by the US FDA in 2025 for adult patients with relapsed or refractory NPM1-mutant acute myeloid leukemia (AML). NPM1 mutations are present in roughly 30 percent of de-novo adult AML cases. Mechanistically ziftomenib disrupts the menin-KMT2A protein-protein interaction that sustains aberrant HOXA9 and MEIS1 expression in NPM1-mutant and KMT2A-rearranged leukemias. The labelled dose is 600 mg orally once daily with food on a continuous 28-day cycle until disease progression or unacceptable toxicity. The pivotal KOMET-001 trial demonstrated a complete remission rate near 25 percent in heavily pre-treated R/R NPM1-mutant AML, with median duration of response above six months. Key safety considerations are differentiation syndrome, QTc prolongation, and cytopenias, all of which require structured first-eight-week monitoring including ECG and electrolytes.

For a patient in Bangladesh with confirmed NPM1-mutant R/R AML, Komzifti is not registered with the Directorate General of Drug Administration (DGDA) and is not stocked through hospital formularies. Supply is therefore organized through Bangladesh's personal-use named-patient import framework, which Reserve Meds coordinates end-to-end with the treating haematologist.

Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.

Access pathway in Bangladesh

Bangladesh's Directorate General of Drug Administration (DGDA), operating under the Ministry of Health and Family Welfare, regulates the import, registration, and dispensing of all medicinal products under the Drugs (Control) Ordinance 1982 and the Bangladesh Drug Rules. For an unregistered specialty oncologic agent such as Komzifti, the legal route is the named-patient personal-use import authorisation: an individual patient, supported by a licensed treating physician in Bangladesh, may import a specified quantity for personal therapeutic use upon DGDA approval. The procedural framework is established and is used routinely for rare oncologic, haematologic, and metabolic therapies sourced from the United States, the United Kingdom, India, and the European Union.

Operationally the pathway runs through the patient's treating haematologist or medical oncologist at one of the principal tertiary centres: National Institute of Cancer Research and Hospital (NICRH) Dhaka, Bangabandhu Sheikh Mujib Medical University (BSMMU), Combined Military Hospital (CMH) Dhaka, or one of the major private centres such as United Hospital, Square Hospital, Evercare Hospital Dhaka, or Labaid Cancer Hospital. The treating physician issues a prescription accompanied by a clinical justification letter referencing the NPM1 mutation report, prior lines of therapy, and the absence of an in-country alternative.

Regulatory and Named-Patient Access details

The DGDA personal-use authorisation is granted on a per-patient, per-shipment basis. The treating physician's letter must cite the FDA approval status, the precise clinical indication, and the rationale for not using locally available alternatives. The DGDA reviews the application and, on approval, issues an import permit which is presented at Hazrat Shahjalal International Airport customs in Dhaka. Reserve Meds operates as the cross-border coordination intermediary: we source Komzifti from a US DSCSA-compliant specialty wholesaler, prepare the manufacturer pedigree certificate and chain-of-custody documentation, and structure the air-freight shipment for hand-off to the patient's nominated agent or hospital pharmacy in Bangladesh.

Komzifti is a heat-stable oral capsule and does not require cold-chain handling, which simplifies logistics relative to biologic agents. Each shipment includes US-pedigree documentation, manufacturer lot and expiry data, and full chain-of-custody records, satisfying DGDA traceability expectations.

Documentation required

The patient and physician should be prepared to provide: a current Bangladeshi national ID (NID) or passport; a recent bone-marrow biopsy report confirming AML with documented NPM1 mutation; the molecular pathology report identifying the specific NPM1 variant; a record of prior induction and salvage therapy with response data; a current prescription from the treating Bangladeshi physician; the physician's clinical justification letter on hospital letterhead; the DGDA personal-use import application form; and proof of payment capacity. Reserve Meds prepares the export-side commercial documentation, US-pedigree certificates, and customs packet.

Typical timeline for Bangladesh

We give you a written timeline estimate for your case before you commit. Week 0 to 1 covers clinical eligibility review and documentation gathering. Week 1 to 3 covers DGDA filing, prescription issuance, and approval. Week 3 to 5 covers procurement from the US wholesaler, export documentation, and air freight to Dhaka. Week 5 to 7 covers customs clearance and final dispensing. Re-supply cycles for continued dosing are typically two to three weeks once the initial DGDA authorisation has been issued and renewed.

Costs and funding considerations

Medicine price: quote on request. You get a written quote for your case before you commit. Bangladesh does not operate a public reimbursement mechanism for unregistered foreign oncology agents. Some patients access partial support through hospital-based welfare funds or charitable trusts (for example the Ahsania Mission Cancer Hospital subsidies), but most cases are self-funded through a combination of family resources, diaspora support, and structured prepayment with Reserve Meds. Private health insurance in Bangladesh rarely covers personal-import unregistered therapy.

Frequently asked questions

• Is the pathway legal in Bangladesh? Yes. It operates under the DGDA personal-use named-patient import authorisation framework provided by the Drugs (Control) Ordinance 1982 and the Bangladesh Drug Rules.
• Does my insurance cover Komzifti? Typically no. Unregistered personal-import oncology therapy generally falls outside private and public reimbursement coverage in Bangladesh.
• What physician credentials are required? A Bangladesh Medical and Dental Council (BMDC) registered physician, typically a haematologist or medical oncologist at a recognised tertiary centre.
• What if Komzifti is in short supply at the US level? Reserve Meds will inform you upfront and decline the case rather than promise a timeline we cannot meet. We do not source from grey-market or unverified channels.
• Can I arrange ongoing re-supply? Yes. Once the initial DGDA authorisation and clinical baseline are established, monthly re-supply is routine.
• Do I need to travel abroad? No. Drug is dispensed to your treating physician in Bangladesh and clinical management remains in-country.

Start a request for Komzifti in Bangladesh

If your haematologist has confirmed NPM1-mutant R/R AML and you want to walk through the Bangladesh pathway in detail, open a case file with Reserve Meds. We will review the eligibility documentation, prepare the DGDA packet alongside your treating physician, and send a written quote for your case.

Ask about a medicine Or message us on WhatsApp